Lung cancer screening

BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening

Retrieved on: 
Tuesday, June 1, 2021
Medicine, Clinical medicine, Cancer screening, Medical tests, Biopsy, Interventional radiology, Lung cancer, Liquid biopsy, Lung cancer screening, Cancer, Screening

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform.
  • This initiative entitled "A Pan Canadian initiative for the development of a liquid biopsy assay for lung cancer screening" is being led by Dr. Philippe Joubert and a team of leading clinicians, academic researchers, and data scientists.
  • The overarching goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk population.
  • BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.

Global Lung Cancer Diagnostic and Screening Test Market to Surpass US$ 3,515.9 Million by 2028, Says Coherent Market Insights (CMI)

Retrieved on: 
Thursday, May 6, 2021
Research, General Health, Pharmaceutical, Oncology, Medical devices, Clinical trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, Medicine, Lung cancer, Clinical medicine, Health, Cancer treatments, Medical software, Qiagen, HER2/neu, Lung cancer screening, Non-small-cell lung carcinoma, Thermo Fisher Scientific, Cancer screening

b"According to Coherent Market Insights, the global lung cancer diagnostic and screening market is estimated to be valued at US$ 1,931.0 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2028).\nThe increasing number of screening test approvals from regulatory bodies is expected to drive growth of the lung cancer diagnostic and screening market during the forecast period.

Key Points: 
  • b"According to Coherent Market Insights, the global lung cancer diagnostic and screening market is estimated to be valued at US$ 1,931.0 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2028).\nThe increasing number of screening test approvals from regulatory bodies is expected to drive growth of the lung cancer diagnostic and screening market during the forecast period.
  • For instance, in June 2020, Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test.
  • The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations, who may be eligible for Enhertu, a HER2 directed antibody drug conjugate (ADC), which is currently in global phase 2 development for HER2 mutated or HER2 overexpressing NSCLC.\nThe increasing number of companion diagnostic approvals from regulatory bodies is expected to drive growth of the global lung cancer diagnostic and screening test market.
  • For instance, in August 2015 GE Healthcare announced to be the first company with a low dose computed tomography (CT) lung cancer screening option that is cleared by the U.S. FDA for lung cancer screening.\nKey players operating in the global lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc ., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.\n"

AACR Annual Meeting 2021: AnchorDx Unveils High-Performance Blood Test for Gastric Cancer Screening

Retrieved on: 
Monday, April 19, 2021
Medicine, Cancer screening, Clinical medicine, Infectious causes of cancer, Branches of biology, American Association for Cancer Research, Lung cancer screening, Screening, Stomach cancer, Cancer

b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.

Key Points: 
  • b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.
  • In addition to superior sensitivity and specificity features, Aurora 2.0 retains its original advantages such as low cost and short turnaround time.
  • In China, the incidence and mortality of gastric cancer rank second (10.5%) and third (12.4%), respectively.
  • In addition, AnchorDxhas a proprietarybig data and artificial intelligence platform designed for early lung cancer screening, diagnosis, and treatment.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/aacr-annual-meeting-2021-anchord...\n"

RSNA: Lung Cancer Screening Predicts Risk of Death from Heart Disease

Retrieved on: 
Thursday, April 15, 2021
Clinical medicine, Medical specialties, Medicine, Lung cancer, Cancer screening, Health effects of tobacco, Lung cancer screening, CT scan, Cardiothoracic surgery, Cardiovascular disease, Cancer

b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.

Key Points: 
  • b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.
  • It even outpaces lung cancer as the leading cause of death in heavy smokers.\nLow-dose CT lung scans are used to screen for lung cancer in high-risk people such as heavy smokers.
  • These CT scans also provide an opportunity to screen for cardiovascular disease by extracting information about calcification in the heart and aorta.
  • The Society is based in Oak Brook, Ill. ( RSNA.org )\nFor patient-friendly information on lung cancer screening, visit RadiologyInfo.org .\nLinda Brooks, Radiological Society of North Aurora, 630-590-7762, [email protected]\n'

Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial ahead of Planned Commercial Test

Retrieved on: 
Wednesday, March 31, 2021
Medicine, Cancer screening, Clinical medicine, Lung cancer, Health effects of tobacco, Medical tests, Health, Lung cancer screening, Screening, CT scan, Cancer, United States Preventive Services Task Force

Based on recently published USPSTF guidelines1, annual lung cancer screening by low-dose CT scan is recommended for 15 million U.S. adults.

Key Points: 
  • Based on recently published USPSTF guidelines1, annual lung cancer screening by low-dose CT scan is recommended for 15 million U.S. adults.
  • An affordable, high performance, broadly available blood test could help increase screening rates and reduce overall lung cancer mortality."
  • Under the partnership, Delfi's test will be studied to potentially increase the number of individuals who are eligible for lung cancer screening.
  • The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries.

Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage

Retrieved on: 
Thursday, March 18, 2021
Federal assistance in the United States, Healthcare reform in the United States, Presidency of Lyndon B. Johnson, Cancer screening, Lung cancer, Lung cancer screening, Medicare, National coverage determination, American College of Radiology, Medicaid, Health, Medicine

That is the message in a letter from the American College of Radiology (ACR), the GO2 Foundation for Lung Cancer and The Society of Thoracic Surgeons (STS), urging the Centers for Medicare & Medicaid Services (CMS) to open a National Coverage Determination (NCD) reconsideration on lung cancer screening.

Key Points: 
  • That is the message in a letter from the American College of Radiology (ACR), the GO2 Foundation for Lung Cancer and The Society of Thoracic Surgeons (STS), urging the Centers for Medicare & Medicaid Services (CMS) to open a National Coverage Determination (NCD) reconsideration on lung cancer screening.
  • Specifically, the groups want CMS to:
    Revise and lower the screening eligibility age to 50 years and smoking history criteria to 20 pack-years in the Medicare population.
  • "Lack of coverage for those who need it has contributed to a severe underuse of lung cancer screening which has undoubtedly cost lives.
  • Swift coverage expansion by Medicare and private insurers would help doctors and allied professionals address racial and regional disparities and strike back against the nation's leading cancer killer by using lung cancer screening to its full advantage," said Debra Dyer, MD, FACR, Chair of the American College of Radiology Lung Cancer Screening Steering Committee.

New USPSTF Lung Cancer Screening Eligibility Thresholds Can Save Lives and Aid Health Equity Efforts

Retrieved on: 
Tuesday, March 9, 2021
Cancer screening, Medicine, Lung cancer, Clinical medicine, Medical tests, Health, Health effects of tobacco, Lung cancer screening, United States Preventive Services Task Force, Screening, Cancer, CT scan

This combined USPSTF and CMS action would enable the medical community to strike a blow against the nation's leading cancer killer by using LCS screening to its full advantage.

Key Points: 
  • This combined USPSTF and CMS action would enable the medical community to strike a blow against the nation's leading cancer killer by using LCS screening to its full advantage.
  • Screening eligibility expansion should spur more providers to start conversations with eligible patients that can ease lung cancer outcomes disparities particularly among women, Black men and those in rural areas .
  • Annual lung cancer screeningwith low-dose computed tomography (LDCT) in high-risk patients significantly reduces lung cancer deaths.1,2 Sadly, less than 15% of Americans who met previous USPSTF lung cancer screening criteria are tested each year.3,4 Given that the American Cancer Society predicts 131,880 lung cancer deaths in 2021 , more-widespread screening could save 30,00060,000 lives in the United States each year.
  • Particularly with the expanded screening thresholds implemented nationwide, this cost-effective test can save more lives than any cancer-screening test in history.

EX Program By Truth Initiative® And McLeod Health Join Forces To Help Employees, Patients Live Tobacco Free

Retrieved on: 
Tuesday, February 16, 2021
Healthcare in South Carolina, McLeod Health, McLeod, Lung cancer, Lung cancer screening, Tobacco smoking, Health, Medicine

The McLeod Healthier You Program will integrate the EX Program into its overall wellness package for employees.

Key Points: 
  • The McLeod Healthier You Program will integrate the EX Program into its overall wellness package for employees.
  • As part of its McLeod Lung Cancer Screening Program outreach, McLeod will also offer the EX Program to deliver even more resources to support lung cancer patients and those people looking to quit tobacco use.
  • Developed in collaboration with Mayo Clinic, the EX Program is an enterprise-level, digital health program for tobacco addiction for employers and health plans.
  • The hospitals within McLeod Health include: McLeod Regional Medical Center, McLeod Health Dillon, McLeod Health Loris, McLeod Health Seacoast, McLeod Health Cheraw, McLeod Health Clarendon and McLeod Behavioral Health.

iBiopsy®: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)

Retrieved on: 
Tuesday, February 16, 2021
Data management, Biotechnology, Technology, Other Health, Health, Radiology, Oncology, Medical devices, Software, Hospitals, Clinical trials, Cancer screening, Medicine, Health, Clinical medicine, Lung cancer screening, Health effects of tobacco, Medical terminology, Prevention, Lung cancer, Screening, United States Preventive Services Task Force, Cancer

Lung cancer is today the number one cancer killer globally and is responsible for approximatively 22% of cancer deaths1.

Key Points: 
  • Lung cancer is today the number one cancer killer globally and is responsible for approximatively 22% of cancer deaths1.
  • Results from these multicentric randomized trials have shown that lung cancer screening using LDCT reduces lung cancer mortality by 2026% in high-risk populations3.
  • In the US, LDCT lung cancer screening for high-risk individuals is included in the United States Preventive Services Task Force (USPSTF) screening guidelines and reimbursed by CMS4.
  • Lung cancer screening programs are under discussion to be implemented in Europe.

Researchers Probe New Territory in Treating Patients with Lung Cancer during COVID-19 Pandemic

Retrieved on: 
Friday, January 29, 2021
Lung cancer, Health effects of tobacco, Cancer, Cancer screening, Health, Lung cancer screening, Lung Cancer Alliance

Eleven months later, the lung cancer research community gathered virtually at the IASLC 2020 World Conference on Lung Cancer Singapore to share a number of research findings examining the intersection of COVID-19 and lung cancer.

Key Points: 
  • Eleven months later, the lung cancer research community gathered virtually at the IASLC 2020 World Conference on Lung Cancer Singapore to share a number of research findings examining the intersection of COVID-19 and lung cancer.
  • The fear of contracting COVID-19 among patients with lung cancer is palpable, and three new research studies presented today underscore how vulnerable patients with lung cancer feel as they cope with the pandemic.
  • The group surveyed 302 patients with lung cancer about anxiety regarding access to lung cancer care, patient preparedness to navigate care, and information needs (Abstract 3800).
  • The Global Lung Cancer Coalition (GLCC) is a partnership of 40 patient organizations across 29 countries, dedicated to improving outcomes for patients with lung cancer.